

IN THE U.S. PATENT AND TRADEMARK OFFICE

Applicant: YOON, JungMan Conf.: Unknown
Appl. No.: NEW (Div. of 10/005,122) Group: Unknown
Filed: August 1, 2003 Examiner: Unassigned
For: ATP SYNTHESIS ACTIVATOR

INFORMATION DISCLOSURE STATEMENT
(SUBMISSION WITH CONTINUATION-IN-PART OR
RULE 1.53(b) CONTINUATION OR DIVISIONAL APPLICATION)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

August 1, 2003

Sir:

Pursuant to 37 C.F.R. §§ 1.97 and 1.98, applicant(s) hereby submit(s) an Information Disclosure Statement for consideration by the Examiner.

I. LIST OF PATENTS, PUBLICATIONS OR OTHER INFORMATION

The patents, publications, or other information submitted for consideration by the Office are listed on the PTO-1449 form(s), attached hereto.

II. REFERENCES PREVIOUSLY CITED OR SUBMITTED

Pursuant to 37 C.F.R. § 1.98(d), consideration of information listed on the PTO-1449 form(s) is requested since any patents, publications, or other information which are listed on the PTO-1449 form(s) but for which copies are not enclosed herewith, were previously cited by or submitted to the PTO in one of the following applications which has been relied upon for an earlier filing date under 35 U.S.C. § 120:

U.S. Appl. No(s).
10/005,122

U.S. Filing Date(s)
December 7, 2001

III. FEES


This Information Disclosure Statement is being filed concurrent with the filing of a continuation-in-part, continuation, or divisional patent application; therefore, no fee is required.

If the Examiner has any questions concerning this IDS or requires a copy of any of the references cited but not provided, he/she is requested to contact the undersigned. If it is determined that this IDS has been filed under the wrong rule, the PTO is requested to consider this IDS under the proper rule and charge the appropriate fee to Deposit Account No. 02-2448.


If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to Deposit Account No. 02-2448 for any additional fee required under 37 C.F.R. §§ 1.16 or 1.17; particularly, extension of time fees.

Respectfully submitted,

BIRCH, STEWART, KOLASCH & BIRCH, LLP

By 
Gerald M. Murphy, Jr., #28,977

P.O. Box 747
Falls Church, VA 22040-0747
(703) 205-8000


GMM/NJR/jeb
1254-0232P

Attachment(s): ☒ PTO-1449(s)

☐ References

☐ Foreign Search Report

☐ Other:

(Rev. 04/29/03)

Form PTO-1449				ATTY DOCKET NO. 1254-0232P		APPLICATION NO. New (Div. of 10/005,122)		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)				APPLICANT YOON, JungMan				
				FILING DATE August 1, 2003		GROUP Unknown		
U.S. PATENT DOCUMENTS								
EXAMINER INITIAL	DOCUMENT NUMBER	Kind	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE	
	US 5,472,731		12/5/1995	Fuisz				
	US 4,343,823		8/10/1982	Todd, Jr. et al.				
	US 4,285,981		8/25/1981	Todd, Jr. et al.				
	US 4,315,947		2/16/1982	Todd, Jr. et al.				
	US 4,283,429		8/11/1981	Todd, Jr. et al.				
	US 5,422,136		6/6/1995	Fuisz				
	US							
	US							
	US							
	US							
FOREIGN PATENT DOCUMENTS								
Office	DOCUMENT NUMBER	Kind	DATE	COUNTRY	CLASS	SUB CLASS	TRANSLATION	
							YES	NO
OTHER DOCUMENTS (Include Name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.)								
	TANAKA, M., <i>Influence of KIPPO On Adverse Affects At Time of Anticancer Irradiation And Chemotherapy</i> , 3 rd Annual Meeting of the Japanese Society for Complementary & Alternative Medicine & Treatment, November 4, 2000, Tokyo, JAPAN.							
	CALERA et al., "Biochemically Active Sesquiterpene Lactones from Ratibida Mexicana", <i>Phytochem.</i> , Vol. 40, No. 2, pp. 419-425, 1995.							
EXAMINER				DATE CONSIDERED				
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

GMM/KJR/jeb
km